The soluble CD40 ligand sCD154 in systemic lupus erythematosus

Journal of Clinical Investigation

Volumn 104, Issue 7, 1999, Pages 947-955

  Kato, Kazunori ^a   Santana Sahagún, Ernesto ^a   Rassenti, Laura Z ^a   Weisman, Michael H ^a   Tamura, Naoto ^b   Kobayashi, Shigeco ^b   Hashimoto, Hiroshi ^b   Kipps, Thomas J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIGEN; CD40 LIGAND; DNA ANTIBODY; GLYCOPROTEIN GP 39; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIGEN DETECTION; ARTICLE; AUTOIMMUNITY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0032742987     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI7014     Document Type: Article

References (45)

1. Swaak, A.J., Aarden, L.A., Statius van Eps, L.W., and Feltkamp, T.E. 1979. Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. Arthritis Rheum. 22:226-235.
2. Takasaki, Y., et al. 1998. Expression of costimulatory molecule CD80 on peripheral blood Tcells in patients with systemic lupus erythematosus. J. Rheumatol. 25:1085-1091.
3. Kovacs, B., Thomas, D.E., and Tsokos, G.C. 1996. Elevated in vivo expression of the costimulatory molecule B7-BB1 (CD80) on antigen presenting cells from a patient with SLE. Clin. Exp. Rheumatol. 14:695-697.
4. Folzenlogen, D., Hofer, M.F., Leung, D.Y., Freed, J.H., and Newell, M.K. 1997. Analysis of CD80 and CD86 expression on peripheral blood B lymphocytes reveals increased expression of CD86 in lupus patients [see comments]. Clin. Immunol. Immunopathol. 83:199-204.
5. Mysler, E., et al. 1994. The apoptosis-1/Fas protein in human systemic lupus erythematosus. J. Clin. Invest. 93:1029-1034.
6. Finck, B.K., Linsley, P.S., and Wofsy, D. 1994. Treatment of murine lupus with CTLA4Ig. Science. 265:1225-1227.
7. Kaneko, Y., et al. 1996. CD40-mediated stimulation of B1 and B2 cells: implication in autoantibody production in murine lupus. Eur. J. Immunol. 26:3061-3065.
8. Linsley, P.S., et al. 1991. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174:561-569.
9. Noelle, R.J., et al. 1992. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc. Natl. Acad. Sci. USA. 89:6550-6554.
10. Ranheim, E.A., and Kipps, T.J. 1993. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J. Exp. Med. 177:925-935.
11. Banchereau, J., et al. 1994. The CD40 antigen and its ligand. Annu. Rev. Immunol. 12:881-922.
12. Clark, E.A., and Ledbetter, J.A. 1994. How B and T cells talk to each other. Nature. 367:425-428.
13. Durie, F.H., Foy, T.M., Masters, S.R., Laman, J.D., and Noelle, R.J. 1994. The role of CD40 in the regulation of humoral and cell-mediated immunity, Immunol. Today. 15:406-411.
14. Yang, Y., and Wilson, J.M. 1996. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science. 273:1862-1864.
15. Grewal, I.S., et al. 1996. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science. 273:1864-1867.
16. Koshy, M., Berger, D., and Crow, M.K. 1996. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J. Clin. Invest. 98:826-837.
17. Desai-Mehta, A., Lu, L., Ramsey-Goldman, R., and Datta, S.K. 1996. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoanribody production. J. Clin. Invest. 97:2063-2073.
18. Early, G.S., Zhao, W., and Burns, C.M. 1996. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J. Immunol. 157:3159-3164.
19. Ma, J., et al. 1996. Autoimmune lpr/lpr mice deficient in CD40 ligand: spontaneous Ig class switching with dichotomy of autoantibody responses. J. Immunol. 157:417-426.
20. Swaak, A.J., Hintzen, R.Q., Huysen, V., van den Brink, H.G., and Smeenk, J.T. 1995. Serum levels of soluble forms of T cell activation antigens CD27and CD25 in systemic lupus erythematosus in relation with lymphocytes count and disease course. Clin. Rheumatol. 14:293-300.
21. Font, J., et al. 1996. Elevated soluble CD27 levels in serum of patients with systemic lupus erythematosus. Clin. Immunol. Immunopathol. 81:239-243.
22. Jodo, S., et al. 1997. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erychematosus (SLE) and other autoimmune diseases. Clin. Exp. Immunol. 107:89-95.
23. Gattorno, M., et al. 1998. Differences in tumor necrosis factor-alpha soluble receptor serum concentrations between patients with Henoch-Schönlein purpura and pediatric systemic lupus erythematosus: pathogenecic implications. J. Rheumatol. 25:361-365.
24. Kriegler, M., Perez, C., DeFay, K., Albert, I., and Lu, S.D. 1988. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell. 53:45-53
25. Luettig, B., Decker, T., and Lohmann-Matthes, M.L. 1989. Evidence for the existence of two forms of membrane tumor necrosis factor: an integral protein and a molecule attached to its receptor. J. Immunol. 143:4034-4038.
26. Grell, M., et al. 1995. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor recepror. Cell. 83:793-802.
27. Ranheim, E.A., and Kipps, T.J. 1995. Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. Cell. Immunol. 161:226-235.
28. Macchia, D., et al. 1993. Membrane tumour necrosis factor-alpha is involved in the polyclonal B-cell activation induced by HIV-infected human T cells. Nature. 363:464-466.
29. Tan, E.M., et al. 1982. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25:1271-1277.
30. Cantwell, M.J., Hua, T., Pappas, J., and Kipps, T.J. 1997. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat. Med. 3:984-989.
31. Liang, M.H., Socher, S.A., Larson, M.G., and Schur, P.H. 1989. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 32:1107-1118.
32. Kato, K., Cantwell, M.J., Sharma, S., and Kipps, T.J. 1998. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J. Clin. Invest. 101:1133-1141.
33. Mazzei, G.J., et al. 1995. Recombinant soluble trimeric CD40 ligand is biologically active. J. Biol. Chem. 270:7025-7028.
34. Armitage, R.J., et al. 1992. Molecular and biological characterization of a murine ligand for CD40. Nature. 357:80-82.
35. Roy, M., Waldschmidt, T., Aruffo, A., Ledbetter, J.A., and Noelle, R.J. 1993. The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells J. Immunol. 151:2497-2510.
36. Castle, B.E., Kishimoto, K., Stearns, C., Brown, M.L., and Kehry, M.R. 1993. Regulation of expression of the ligand for CD40 on T helper lymphocytes. J. Immunol 151:1777-1788.
37. Hermann, P., et al. 1993. Expression of a 32-kDa ligand for the CD40 antigen on activated human T lymphocytes. Eur. J. Immunol. 23:961-964.
38. Graf, D., et al. 1995. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur. J. Immunol. 25:1749-1754.
39. Wiley, J.A., Geha, R., and Harmsen, A.G. 1997. Exogenous CD40 ligand induces a pulmonary inflammation response. J. Immunol. 158:2932-2938.
40. Jumper, M.D., Nishioka, Y., Davis, L.S., Lipsky, P.E., and Meek, K. 1995. Regulation of human B cell function by recombinant CD40 ligand and other TNF-related ligands. J. Immunol. 155:2369-2378.
41. Crowe, P.D., et al. 1995. A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J. Exp. Med. 181:1205-1210.
42. Kayagaki, N., et al. 1995. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182:1777-1783.
43. Henn, V., et al. 1998. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 391:591-594.
44. Yellin, M.J., et al. 1995. Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediared signals. J. Exp. Med. 182:1857-1864.
45. van Kooten, C., et al. 1997. Possible role for CD40-CD40L in the regulation of interstitial infiltration in the kidney. Kidney Int. 51:711-721.